High expression of SMARCA4 was significantly associated (COX P ≤ 0.01) with a poor prognosis in breast and ovarian cancer, lung adenocarcinoma, liposarcoma and uveal melanoma datasets (Fig. 2a). This evidence concerns the gene SMARCA4 and ovarian cancer.